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ABSTRACT
Triple immunosuppression is very pivotal in maintaining the graft in case of renal transplantation. But because of severe immunosuppression, always 
there is chance of severe adverse effects. Hematological toxicity is usually very common but dreaded in case of renal transplant patients. Here, we 
report a case of valganciclovir-induced drop in platelet counts in a postrenal transplant patient.
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INTRODUCTION
Renal transplantation along with triple immunosuppression remains 
the gold standard treatment for end-stage renal disease. Renal 
transplant had gained importance as it prolongs the life of patients with 
kidney failure by replacing the diseased kidney with a new kidney from 
the donor. Renal transplant survival has increased mainly due to proper 
perioperative care as well treatment with antirejection drugs [1]. Triple 
immunosuppression causes various side effects such as nephrotoxicity, 
infections, new-onset diabetes after transplant, hypertension, weight 
gain, dyslipidemia, and neurotoxicities in various cases [2]. However, 
one of the major concerns among clinicians performing renal 
transplantation is patients developing hematological disorders usually 
due to infections or because of immunosuppressive drugs. Hence, we 
report a case of valganciclovir-induced thrombocytopenia in a postrenal 
transplant recipient in a tertiary care hospital in southern India.
CASE REPORT
Informed consent was obtained from the patient. A 43-year-old post-
cadaveric renal transplant on 11.11.2016, for Stage V chronic kidney 
disease due to adult polycystic kidney disease was put on triple 
immunosuppression with tacrolimus, mycophenolate mofetil (MMF), 
wysolone along with valganciclovir, and single strength cotrimoxazole 
for cytomegalovirus (CMV) prophylaxis. Induction therapy was also 
given with antithymocyte globulin in this patient. He was admitted 
with persistent leukopenia and transaminitis on 29.12.2016. On 
examination, his vitals were stable, no graft tenderness, no tremors, 
normal oral cavity, and no systemic findings. His lab reports showed 
normal renal function tests along with leukopenia and elevated 
transaminases levels. Hence, MMF, valganciclovir, and cotrimoxazole 
were stopped. CMV infection was suspected and patient was started on 
IV ganciclovir and IV hydration. In view of febrile neutropenia, he was 
started on IV teicoplanin and IV cefepime. His blood culture was sterile 
and his bone marrow culture was negative for epstein barr virus (EBV) 
and CMV. He was given three doses of granulocyte-monocyte colony-
stimulating factor (GM-CSF) and white blood cell counts recovered back 
to normal.
So again, the patient was restarted with MMF and IV ganciclovir was 
changed to oral valganciclovir. However, the patient was put on high 
dose of 900 mg, twice daily, valganciclovir in view awaiting CMV, 
polymerase chain reaction (PCR) report was given as prophylaxis to 
avoid graft failure. The patient was discharged on 03.01.2016 and was 
asked to review in 2 days with complete blood counts along with CMV 
PCR report. On 05.01.2015, patient returned for follow-up with sudden 
drop in platelet counts (Table 1) for the first time in 2 months and 
PCR was negative for CMV. Hence, at this stage CMV was ruled out and 
cause of thrombocytopenia was found to be high-dose valganciclovir. 
Tacrolimus-induced thrombotic microangiopathy was also ruled 
because patient renal function test was normal. Others concomitant 
drugs causing thrombocytopenia was also ruled out. Hence, dose 
of valganciclovir was reduced to 450 mg twice daily and patient was 
asked to review in 4 days. On 09.01.2016, his platelet counts reverted to 
normal (Table 1). Thereby, it was proved valganciclovir was the cause 
for thrombocytopenia as de-challenge was done in our case by reducing 
the dose.
DISCUSSION
Blood disorders affecting renal transplant patients can be classified 
common and uncommon serious disorders. The former includes post-
transplant erythrocytosis, post-transplant anemia and post-transplant 
cytopenias, and the latter includes thrombotic microangiopathies, 
hemophagocytic syndrome, therapy related acute myeloid leukemia, and 
myelodysplasia. With a wide range of etiological factors playing a role 
in the development of blood disorders among renal transplant patient’s 
infections and immunosuppressive treatment plays a major etiological 
role and remains a dreaded threat in development of life-threatening 
hematological complications [3]. Triple immunosuppression for 
prevention of graft versus host disease in renal transplant usually 
includes a calcineurin inhibitor either tacrolimus or cyclosporine, an 
antiproliferative agent like MMF or azathioprine and corticosteroids. 
As infections increase the chance of graft failure, usually prophylaxis is 
given with valganciclovir and cotrimoxazole [4].
Valganciclovir, an effective prodrug of ganciclovir is given orally and is 
effective as intravenous ganciclovir in the prophylaxis of CMV infection 
in solid organ transplant recipients. It helps in reducing the CMV 
resistance to drugs in transplant patients and it provides more systemic 
exposure of ganciclovir when compared to intravenous ganciclovir. 
Hence, valganciclovir is an effective alternative to other anti-CMV 
agents in solid organ transplant patients [5]. Valganciclovir is an L valyl 
ester of ganciclovir and it is an orally acting prodrug. After being taken 
orally, it gets converted into active ganciclovir by cleavage by Esterases 
in the intestinal wall and liver. In CMV-infected ganciclovir undergoes 
phosphorylation to monophosphate form due to CMV-encoded UL97 
protein kinase. Then, monophosphate form is converted to diphosphate 
and triphosphate forms by rapidly acting cellular kinases. Ganciclovir 
triphosphate inside the CMV-infected cell prevents DNA replication by 
competing with deoxyguanosine triphosphate which is a substrate for 
DNA polymerase. It also inhibits viral DNA replication by inhibiting DNA 
chain elongation [6]. It is known to cause various side effects which 
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includes nausea, vomiting, diarrhea, severe hematological toxicity such 
as anemia, bone marrow suppression, and neurological toxicity [6].
Thrombocytopenia is defined as platelet counts <1.5 lakhs. 
Thrombocytopenia is a troublesome complication in renal transplant 
patient occurring usually after the 1st year following transplantation, 
but sometimes, it can occur even in the first 3 months. The major causes 
of thrombocytopenia in transplant setting include infections with CMV/
EBV virus, folate/vitamin B12 deficiency, microangiopathies, bone 
marrow suppression with immunosuppressive agents, acute rejection 
episodes, and antiplatelet antibody therapy. Leukopenia and anemia 
usually overlaps thrombocytopenia in renal transplant settings. Drugs 
associated with thrombocytopenia includes calcineurin inhibitors such 
as tacrolimus causing thrombotic microangiopathy resulting in graft 
rejection, valganciclovir, ganciclovir, linezolid, antithymocyte globulin, 
and heparin [3].
In our case, valganciclovir, MMF and cotrimoxazole were stopped 
when patient first came with complaints of leukopenia and later 
ganciclovir intravenously was given for 1 week in view of prophylaxis 
for CMV/EBV/parvovirus infections along with antibiotics. Later as 
leukopenia reverted to normal with three doses of GM-CSF patient 
and bone marrow CMV/EBV/parvovirus was negative, patient was 
restarted with MMF and ganciclovir was changed to high-dose oral 
valganciclovir, 900 mg twice daily awaiting CMV PCR reports to rule 
out any possibility of CMV infection. 2 days’ patient had drop in 
platelet counts and valganciclovir given in high dose was suspected 
to be the causative agent. Tacrolimus induced HUS was ruled out as 
renal function test was normal and other concomitant drugs causing 
thrombocytopenia were ruled out. CMV PCR report was negative 
ruling CMV as the cause of thrombocytopenia. Hence, the dose of 
valganciclovir was reduced to 450 mg twice daily and platelet counts 
came back to normal in 4 days.
Mechanism suspected here is direct bone marrow toxicity caused 
by high-dose valganciclovir and our case is similar to a case series 
in literature where four cases of bone marrow toxicity causing 
thrombocytopenia was reported with high-dose valganciclovir 
using 900 mg/day in post-transplant patients despite persistent 
renal failure [7]. Furthermore, literature evidence says incidence of 
thrombocytopenia with low-dose valganciclovir as prophylaxis for 
CMV infections in post-transplant patients was 24% and almost 20% 
of patients discontinued valganciclovir due to thrombocytopenia [8].
Causality assessment was done using Naranjo’s scale [9] for establishing 
a causal relationship and a probable causal relationship was ascribed. 
Severity scale was done using Hartwig’s scale [10] and adverse reaction 
was found to be of mild severity, preventability assessment was done 
using Thornton’s scale [11] and adverse reaction was found to be not 
preventable (Table 2).
CONCLUSION
Valganciclovir being a very effective drug in the treatment as well 
prophylaxis of CMV infections in renal transplant recipients, possibility 
of thrombocytopenia when used in high dose should be kept in mind 
as evidence says even low-dose prophylaxis for long period’s causes 
thrombocytopenia. Furthermore, the renal function of the patient 
should be taken into consideration as valganciclovir is eliminated via 
the kidneys and poor renal function can have a very bad consequence 
on the patient resulting in grave toxicities. Hence, further prospective 
study can be done comparing the efficacy of high-dose valganciclovir 
versus low-dose valganciclovir in postrenal transplant patients and the 
effect of renal failure on the outcome of treatment.
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Table 1: Platelet counts before and after valgancyclovir
Dates Platelet counts
23.11.2016 (450 mg) 254×103/UL
05.01.2017 (900 mg) 124×103/UL
09.01.2017 (450 mg) 153×103/UL
Table 2: Adverse drug assesment
Scales Assesment
Naranjo’s Probable
Hartwig’s Mild severity
Thornton’s Not preventable
